These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34554032)

  • 1. A novel oral formulation of BIO 300 confers prophylactic radioprotection from acute radiation syndrome in mice.
    Singh VK; Fatanmi OO; Wise SY; Carpenter A; Nakamura-Peek S; Serebrenik AA; Kaytor MD
    Int J Radiat Biol; 2022; 98(5):958-967. PubMed ID: 34554032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Radioprotectant, BIO 300, Protects the Lungs from Total-Body Irradiation Injury in C57L/J Mice.
    Singh VK; Serebrenik AA; Fatanmi OO; Wise SY; Carpenter AD; Janocha BL; Kaytor MD
    Radiat Res; 2023 Mar; 199(3):294-300. PubMed ID: 36689635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative proteomic analysis of serum from nonhuman primates administered BIO 300: a promising radiation countermeasure.
    Girgis M; Li Y; Ma J; Sanda M; Wise SY; Fatanmi OO; Kaytor MD; Cheema AK; Singh VK
    Sci Rep; 2020 Nov; 10(1):19343. PubMed ID: 33168863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure.
    Singh VK; Seed TM
    Expert Opin Investig Drugs; 2020 May; 29(5):429-441. PubMed ID: 32450051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BIO 300: A Prophylactic Radiation Countermeasure for Acute Radiation Syndrome.
    Singh VK; Serebrenik AA; Wise SY; Petrus SA; Fatanmi OO; Kaytor MD
    Mil Med; 2024 Aug; 189(Supplement_3):390-398. PubMed ID: 39160790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary Promising Findings for Manganese Chloride as a Novel Radiation Countermeasure Against Acute Radiation Syndrome.
    Hood MN; Ayompe E; Holmes-Hampton GP; Korotcov A; Wuddie K; Aschenake Z; Ahmed AE; Creavalle M; Knollmann-Ritschel B
    Mil Med; 2024 Aug; 189(Supplement_3):598-607. PubMed ID: 39160887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing Pediatric Mouse Models of the Hematopoietic Acute Radiation Syndrome and the Delayed Effects of Acute Radiation Exposure.
    Patterson AM; Sellamuthu R; Plett PA; Sampson CH; Chua HL; Fisher A; Vemula S; Feng H; Katz BP; Tudor G; Miller SJ; MacVittie TJ; Booth C; Orschell CM
    Radiat Res; 2021 Apr; 195(4):307-323. PubMed ID: 33577641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status.
    Singh VK; Hauer-Jensen M
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27153057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism and therapeutic window of a genistein nanosuspension to protect against hematopoietic-acute radiation syndrome.
    Landauer MR; Harvey AJ; Kaytor MD; Day RM
    J Radiat Res; 2019 May; 60(3):308-317. PubMed ID: 31038675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further Characterization of Multi-Organ DEARE and Protection by 16,16 Dimethyl Prostaglandin E2 in a Mouse Model of the Hematopoietic Acute Radiation Syndrome.
    Wu T; Pelus LM; Plett PA; Sampson CH; Chua HL; Fisher A; Feng H; Liu L; Li H; Ortiz M; Chittajallu S; Luo Q; Bhatwadekar AD; Meyer TB; Zhang X; Zhou D; Fischer KD; McKinzie DL; Miller SJ; Orschell CM
    Radiat Res; 2023 May; 199(5):468-489. PubMed ID: 37014943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome.
    Patterson AM; Wu T; Chua HL; Sampson CH; Fisher A; Singh P; Guise TA; Feng H; Muldoon J; Wright L; Plett PA; Pelus LM; Orschell CM
    Radiat Res; 2021 Feb; 195(2):115-127. PubMed ID: 33302300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Metabolomic Serum Signature from Nonhuman Primates Treated with a Radiation Countermeasure, Gamma-tocotrienol, and Exposed to Ionizing Radiation.
    Pannkuk EL; Laiakis EC; Fornace AJ; Fatanmi OO; Singh VK
    Health Phys; 2018 Jul; 115(1):3-11. PubMed ID: 29787425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioprotective effect of newly synthesized toll-like receptor 5 agonist, KMRC011, in mice exposed to total-body irradiation.
    Kim JY; Park JH; Seo SM; Park JI; Jeon HY; Lee HK; Yoo RJ; Lee YJ; Woo SK; Lee WJ; Choi CM; Choi YK
    J Radiat Res; 2019 Jul; 60(4):432-441. PubMed ID: 31165150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing polyphenolic acetates as radiation countermeasure agents: current status and future perspectives.
    Venkateswaran K; Shrivastava A; Prasad AK; Parmar VS; Dwarakanath BS
    Drug Discov Today; 2020 Apr; 25(4):781-786. PubMed ID: 32062010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors.
    Chua HL; Plett PA; Sampson CH; Katz BP; Carnathan GW; MacVittie TJ; Lenden K; Orschell CM
    Health Phys; 2014 Jan; 106(1):21-38. PubMed ID: 24276547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioprotective properties of tocopherol succinate against ionizing radiation in mice.
    Singh VK; Singh PK; Wise SY; Posarac A; Fatanmi OO
    J Radiat Res; 2013 Mar; 54(2):210-20. PubMed ID: 23038797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEGylated IL-11 (BBT-059): A Novel Radiation Countermeasure for Hematopoietic Acute Radiation Syndrome.
    Kumar VP; Biswas S; Sharma NK; Stone S; Fam CM; Cox GN; Ghosh SP
    Health Phys; 2018 Jul; 115(1):65-76. PubMed ID: 29787432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX-301: a novel medical countermeasure for hematopoietic acute radiation syndrome in mice.
    Satyamitra M; Cary L; Dunn D; Holmes-Hampton GP; Thomas LJ; Ghosh SP
    Sci Rep; 2020 Feb; 10(1):1757. PubMed ID: 32019942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed effects of radiation exposure in a C57L/J mouse model of partial body irradiation with ~2.5% bone marrow shielding.
    Beach T; Bakke J; McDonald JT; Riccio E; Javitz HS; Nishita D; Kapur S; Bunin DI; Chang PY
    Front Public Health; 2024; 12():1349552. PubMed ID: 38544733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and metabolomic studies with a BIO 300 Oral Powder formulation in nonhuman primates.
    Li Y; Girgis M; Jayatilake M; Serebrenik AA; Cheema AK; Kaytor MD; Singh VK
    Sci Rep; 2022 Aug; 12(1):13475. PubMed ID: 35931769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.